ARL8B KO cell line available to order. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.
Images
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Form
- Liquid
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1
Alternative names
ADP ribosylation factor like 10C, ADP ribosylation factor like 8B, ADP-ribosylation factor-like protein 10C, ADP-ribosylation factor-like protein 8B, ARL10C, ARL8B_HUMAN, FLJ10702, Gie1, Novel small G protein indispensable for equal chromosome segregation 1
Recommended products
ARL8B KO cell line available to order. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Form
- Liquid
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1
- Disease
- Adenocarcinoma
- Concentration
Properties
- Gene name
- ARL8B
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing
- Zygosity
- Homozygous
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Handling procedures
- Initial handling guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.- Subculture guidelines
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 2x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
- Culture medium
- DMEM (High Glucose) + 10% FBS
- Cryopreservation medium
- Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Storage
- Shipped at conditions
- Dry Ice
- Appropriate short-term storage conditions
- -196°C
- Appropriate long-term storage conditions
- -196°C
Notes
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
ARL8B also known as ADP-ribosylation factor-like protein 8B is a small GTPase with an approximate molecular mass of 22 kDa. It mainly localizes to the lysosomal membrane. This protein plays an important role in the regulation of intracellular trafficking and lysosome positioning. ARL8B is expressed across many tissues suggesting its involvement in broad cellular functions.
- Biological function summary
ARL8B helps manage the proper function of lysosomes by facilitating their movement and fusion with other cellular compartments. It forms a complex with other proteins such as PLEKHM2 and HOPS which are necessary for tethering events during lysosomal trafficking. This protein contributes to cellular processes such as autophagy and antigen presentation influencing the cell's ability to maintain homeostasis and effectively respond to external stimuli.
- Pathways
ARL8B participates in the autophagy pathway and plays a part in the lysosome-related processes. It works closely with proteins like the kinesin motor proteins which drive the movement of lysosomes along microtubules. Through these interactions ARL8B coordinates with other autophagy-related proteins to ensure efficient degradation of cellular debris and recycling of components which are important for cellular health and function.
- Associated diseases and disorders
ARL8B has links to neurodegenerative diseases and immune system dysfunctions. Dysregulation of lysosomal positioning and movement caused by abnormal ARL8B function can lead to conditions such as Charcot-Marie-Tooth disease and impaired immune responses. Furthermore ARL8B interacts with proteins like Rab7a which can have implications in disease pathways emphasizing its significant role in maintaining cellular balance.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
Sanger Sequencing - Human ARL8B knockout HeLa cell line (ab265325)
Homozygous: 1 bp insertion in exon 1.
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com